Purpose: To determine the toxicities, pharmacokinetics, and maximally tolerated doses of
oxaliplatin in patients with hepatic impairment and to develop formal guidelines for …

Oxaliplatin, which was recently approved by the US Food and Drug Administration for the
treatment of advanced colorectal cancer, is often administered to patients with altered liver …

4169 Background: Prolonged survival for patients (pts) with unresectable hepatocellular
cancer (HCC) has remained elusive, with median overall survival consistently less than 6 …

Purpose: This study was undertaken to determine the toxicities, pharmacokinetics, and
maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop …

Purpose: Prolonged survival for patients with unresectable hepatocellular carcinoma (HCC)
is consistently reported at lower than 6 months. Oxaliplatin has recently demonstrated …

Oxaliplatin is an approved agent with clinical activity in the treatment of advanced colorectal
cancer. Preliminary pharmacokinetic evidence suggests that oxaliplatin is predominantly …

Background: Oxaliplatin, a platinum compound, has been commonly used around the world
for treating advanced colorectal cancer. The generally recommended dose and schedule of …

In early clinical trials, oxaliplatin has demonstrated significant activity against colorectal
cancer, both as a single agent and in combination with 5-fluorouracil (5-FU) and folinic acid …

Abstract Oxaliplatin (cis-[(1 R, 2 R)-1, 2-cyclohexanediamine-N, N′] oxalato (2-)-O, O′]
platinum; Eloxatine) is a novel platinum coordination complex used for the treatment of …

Aim: to evaluate the therapeutic efficacy of oxaliplatin and to analyze the pharmacokinetics
of both ultrafiltrable (free) and protein–bound platinum in patients with metastatic colon …